DGX vs DVA
Quest Diagnostics Inc. and DaVita Inc., side by side — 10 fiscal years reported in USD, drawn from SEC filings.
Most recent reported year
| Metric | DGX | DVA |
|---|---|---|
| Revenue | $11.0B | $13.6B |
| Net income | $992.0M | $746.8M |
| Gross margin | 33.2% | · |
| Net margin | 9.5% | 7.9% |
| Return on equity | 14.2% | · |
| Diluted EPS | $8.75 | $9.84 |
| Dividend / share | · | · |
| Payout ratio | 35.6% | 0.0% |
| Free cash flow | $1.4B | $1.3B |
| Equity | $7.2B | $-651.1M |
| Net debt / equity | 0.73× | · |
| Current ratio | 1.04× | 1.29× |
| Revenue CAGR 5y | 3.2% | 3.4% |
| Profit CAGR 5y | −7.1% | −0.7% |
DVA bills 1.2× the revenue of DGX, and DGX keeps more of each dollar of revenue as profit (9.5% against 7.9%).
The stronger figure of the pair is set in bold. That is arithmetic, not a recommendation — this page does not pick a winner. "·" marks a figure not available in our data.
10 years side by side
| Fiscal year | DGX | DVA |
|---|---|---|
| FY2025 | $11.0B | $13.6B |
| FY2024 | $9.9B | $12.8B |
| FY2023 | $9.3B | $12.1B |
| FY2022 | $9.9B | $11.6B |
| FY2021 | $10.8B | $11.6B |
| FY2020 | $9.4B | $11.6B |
| FY2019 | $7.7B | $11.4B |
| FY2018 | $7.5B | $11.4B |
| FY2017 | $7.4B | $10.9B |
| FY2016 | $7.2B | $10.7B |
Bottom line
| Fiscal year | DGX | DVA |
|---|---|---|
| FY2025 | $992.0M | $746.8M |
| FY2024 | $871.0M | $936.3M |
| FY2023 | $854.0M | $691.5M |
| FY2022 | $946.0M | $560.4M |
| FY2021 | $2.0B | $978.5M |
| FY2020 | $1.4B | $773.6M |
| FY2019 | $858.0M | $811.0M |
| FY2018 | $736.0M | $159.4M |
| FY2017 | $772.0M | $663.6M |
| FY2016 | $645.0M | $879.9M |
16 fiscal years
| Fiscal year | Difference | Ahead |
|---|---|---|
| FY2025 | −$2,608,069,000 | DVA |
| FY2024 | −$2,943,550,000 | DVA |
| FY2023 | −$2,888,147,000 | DVA |
| FY2022 | −$1,726,894,000 | DVA |
| FY2021 | −$830,797,000 | DVA |
| FY2020 | −$2,113,604,000 | DVA |
| FY2019 | −$3,662,479,000 | DVA |
| FY2018 | −$3,873,851,000 | DVA |
| FY2017 | −$3,474,634,000 | DVA |
| FY2016 | −$3,493,467,000 | DVA |
| FY2015 | −$2,489,245,000 | DVA |
| FY2014 | −$5,360,106,000 | DVA |
| FY2013 | −$4,618,050,000 | DVA |
| FY2012 | −$803,280,000 | DVA |
| FY2011 | +$660,194,000 | DGX |
| FY2010 | +$1,040,510,000 | DGX |
The higher-revenue side has changed between DGX and DVA over this period. The gap has widened since the earliest year compared.
16 of 19 comparable fiscal years — a year missing data on either side is not counted.
16 fiscal years
| Fiscal year | Difference | Ahead |
|---|---|---|
| FY2025 | +1.6 pp | DGX |
| FY2024 | −0.4 pp | DVA |
| FY2023 | +1.9 pp | DGX |
| FY2022 | +3.5 pp | DGX |
| FY2021 | +8.9 pp | DGX |
| FY2020 | +7.3 pp | DGX |
| FY2019 | +2.8 pp | DGX |
| FY2018 | +7.5 pp | DGX |
| FY2017 | +3.5 pp | DGX |
| FY2016 | −0.0 pp | DVA |
| FY2015 | +5.8 pp | DGX |
| FY2014 | +1.2 pp | DGX |
| FY2013 | +5.9 pp | DGX |
| FY2012 | +0.2 pp | DGX |
| FY2011 | −1.7 pp | DVA |
| FY2010 | +2.6 pp | DGX |
The higher net margin has changed hands between DGX and DVA over this period.
16 of 19 comparable fiscal years — a year missing data on either side is not counted.
Standard deviation, each side
DGX's net margin has been more volatile than DVA's over the 16 comparable fiscal years — 3.0 percentage points of standard deviation against 1.9.
16 of 19 comparable fiscal years — a year missing data on either side is not counted.
Year by year
The lead in net margin changed hands between DGX and DVA over these 16 fiscal years — DGX led in 13 and DVA in 3.
16 of 19 comparable fiscal years — a year missing data on either side is not counted.
Standard deviation, each side
DVA's return on equity has been more volatile than DGX's over the 17 comparable fiscal years — 39.5 percentage points of standard deviation against 4.3.
17 of 19 comparable fiscal years — a year missing data on either side is not counted.
Year by year
The lead in return on equity changed hands between DGX and DVA over these 17 fiscal years — DGX led in 4 and DVA in 13.
17 of 19 comparable fiscal years — a year missing data on either side is not counted.